Skip to main navigation Skip to search Skip to main content

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections. . .

    Project: Research

    Project Details

    StatusFinished
    Effective start/end date01/4/19 → 01/3/22

    Funding

    • Shire Human Genetic Therapies Inc.: $24,475.00